mRNA-based prophylactic vaccinesin collaboration with GSK

Addressing infectious diseases

CV0501

COVID-19 vaccine candidate(Modified)

Partner

CV2CoV

COVID-19 vaccine candidate(Unmodified)

Partner

FLU SV mRNA

Influenza vaccine candidate(Modified)

Partner

CVSQIV

Influenza vaccine candidate(Unmodified)

Partner

Other infectious diseases

Partner

mRNA-based prophylactic vaccines

Addressing infectious diseases

CVnCoV

COVID-19 vaccine candidate

Partner

CV7202

Rabies vaccine candidate

CV7202 – Phase 1

CV7202 is a prophylactic mRNA-based vaccine encoding the rabies virus glycoprotein, RABV-G, formulated with next generation lipid nanoparticle (LNP).

CV7202 is currently being studied in a phase 1, dose-escalation, open-label clinical trial.

Study objectives:

  • Primary: Safety, reactogenicity
  • Secondary: Potential protective immune response, immunogenicity via geometric mean virus neutralization tests (VNT)

Rabies, a viral disease that causes inflammation in the brain, still occurs in more than 150 countries around the globe, with the infection responsible for more than 60,000 deaths every year, primarily in China and India.

More information about the CV7202 study can be found at ClinicalTrials.gov (NCT03713086).

Lassa, yellow fever

Partner

Respirational syncytial virus

Various projects

Rota, malaria, universal influenza

Partner

Ongoing Research – Malaria & Rota – Research

With support from the Bill & Melinda Gates Foundation, research is being conducted to leverage CureVac’s prophylactic vaccine technology to develop mRNA-based vaccines to prevent infectious diseases that disproportionately affect people in the world’s poorest countries.

RNA-based cancer immunotherapies

CV8102

Oncology candidate

CV8102 (Study 1) – Phase 1

CV8102, a TLR7/8/RIG-1 agonist based on noncoding single stranded RNA, is designed to modulate the tumor microenvironment after intratumoral injection and to induce a systemic immune response to control injected as well as non-injected distant lesions.

CV8102 is currently being studied in a Phase 1, open-label, dose escalation and expansion study, which is enrolling patients with advanced melanoma, cutaneous squamous cell carcinoma, squamous cell carcinoma of head and neck, or adenoidcystic carcinoma, and superficially injectable tumor lesions.

The trial is testing escalating doses of single agent CV8102 and CV8102 in combination with licensed anti-PD-1 antibodies.

Study objectives:

  • Primary: Safety, tolerability
  • Secondary: Clinical efficacy, changes in various immune parameters in blood and tumor tissue

More information about the CV8102 study can be found at ClinicalTrials.gov.

Tumor associated antigens (TAA)

Undisclosed

Shared neo-antigens

Undisclosed

Molecular therapies

Cas9 gene-editing

Partner

Gene-editing – Pre-clinical

CureVac is collaborating with CRISPR Therapeutics to develop novel Cas9 mRNA constructs, which have improved properties for gene editing applications, such as increased potency, decreased duration of expression, and reduced potential for immunogenicity.

For more information about our partnership with CRISPR click here.

Liver Diseases

Ocular diseases

Partner

Therapeutic antibodies

Partner